- Policy
- Generic for Xeljanz by Boryung was first approved
- by Lee, Tak-Sun Sep 1, 2020 06:12am
- Boryeong's generic for Xeljanz was first approved. On the 27th, the MFDS granted Boryung Tofacitinib 5mg (Tofacitinib aspartate) by Boryung as a drug for data-based re-evaluation. This product is a salt-modified product of the original product Gelzanz 5mg (Tofacitinib citrate), which was approved in April 2014, and is the first approved pr
- Policy
- Ongentys listed at ₩2,515 & Prevymis at ₩145,000
- by Kim, Jung-Ju Sep 1, 2020 06:12am
- SK Chemicals' parkinson's syndrome treatment, Ongentys 50mg (Opicapone) will be listed at &8361;2,515 per capsule starting October 1st. MSD Korea's CMV infection and disease prevention drug Prevymis (Letermovir) 240mg was listed at &8361;145,000, and Ferring Korea's infertility treatment, Rekovelle PFS (Follitropin delta) is applied at &83
- Policy
- 21 generics for Forxiga acquired the exclusivity from April
- by Lee, Tak-Sun Aug 28, 2020 06:17am
- Forxiga (Dapagliflozin), generic for SGLT-2 inhibitory diabetes treatment has obtained generic exclusivity that will be applied from April 2023. This is because the material patent ends in April 2023. Excluding this patent, the pharmaceutical companies that acquired the generic exclusivity succeeded in patent challenges. However, as a second
- Policy
- Prevymis and Rekovelle PFS were newly listed
- by Kim, Jung-Ju Aug 26, 2020 06:23am
- Xarelto 2.5mg’s benefit standard will be expanded. Prevymis (Letemovir), a vaccine for preventing MSD virus from Korea, and Rekovelle (Follitropin Delta), a follicle-stimulating hormone injection by Ferring Pharmaceutical Korea, are newly applied next month, and a new reimbursement standard will be established. Pharmaceutical Reimbursemen
- Policy
- Jardiance follow-on drugs seek approval to launch in 5 years
- by Lee, Tak-Sun Aug 25, 2020 06:14am
- A promising antidiabetic treatment, sodium-glucose co-transporter-2 (SGLT2) inhibitors are seeing their follow-on drugs emerging for an early market release after winning approval from the South Korean health authority. Due to the extended patent term, however, the new follow-on drugs’ release would have to for another two years at leas
- Policy
- Started to develop the generic for Norspan Patch
- by Lee, Tak-Sun Aug 25, 2020 06:11am
- The development of generic drug for 'Nospan Patch', a narcotic pain reliever that has been growing recently, has begun. Samyang Biopharm has received approval for the bioequivalence test from the Ministry of Food and Drug Safety. Northpan patch has no patents on the PMS and patent list, but there is no same active ingredient so far. On
- Policy
- Followup of drug price agreement, possible by electronically
- by Kim, Jung-Ju Aug 25, 2020 06:11am
- When the NHIS concludes a drug price negotiation with a pharmaceutical company, a legal basis will be prepared for notifying the company in writing or electronically of the details of the subsequent proceedings. The purpose of this is to increase administrative convenience so that insurance benefits work more efficiently. The MOHW announc
- Policy
- Forsteo reduced pricing effective from Aug. 25
- by Kim, Jung-Ju Aug 25, 2020 06:10am
- As the South Korean court ruled against Lilly Korea’s litigation claiming unfair pricing reduction on its osteoporosis treatment Forsteo (teriparatide), the government would execute the order as planned initially. The insured pricing reduction would be enforced on Aug. 25, but it could be suspended again if the company decides to take
- Policy
- Democratic Party submits 5 bills to curb spiking COVID-19
- by Lee, Jeong-Hwan Aug 24, 2020 06:19am
- The ruling party readies for a full-on quarantine measures by introducing a series of bills to curb COVID-19 resurging in South Korea centering a far-right church in Seoul metropolitan area. On Aug. 20 and 21, the Democratic Party submitted five bills to the National Assembly (NA) to strengthen the existing regulations to contain the rap
- Policy
- Tagrisso and Eliquis pricing lowered 4% through PVA
- by Kim, Jung-Ju Aug 24, 2020 06:18am
- The insured pricing of AstroZeneca Korea’s Tagrisso tablet (osimertinib mesylate) and Bristol-Myers Squibb’s (BMS) Eliquis tablet (apixaban) would be lowered by approximately 4 percent from next month due to pricing-volume agreement (PVA). According to the pharmaceutical industry sources, South Korea’s Ministry of Health and Welfare (MOHW
